ACADL suppresses PD-L1 expression to prevent cancer immune evasion by targeting Hippo/YAP signaling in lung...

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Lung cancer remains a leading cause of cancer mortality worldwide.
• Cancer immune evasion presents a significant challenge for effective lung cancer treatment.
• Long-chain Acyl-CoA dehydrogenase (ACADL) is recognized as a tumor suppressor, but its role in lung adenocarcinoma (LUAD) is uncharacterized.

Purpose of the Study:

• To investigate the function of ACADL in LUAD.
• To determine ACADL's impact on tumor proliferation, apoptosis, and immune evasion.
• To elucidate the molecular mechanisms underlying ACADL's effects, particularly its regulation of PD-L1 expression via the Hippo/YAP pathway.

Main Methods:

• Analysis of ACADL expression and its correlation with patient outcomes (overall survival and progression-free survival) in LUAD.
• Experimental investigation of ACADL's effects on LUAD cell proliferation and chemosensitivity.
• Exploration of ACADL's role in regulating PD-L1 expression and its connection to the Hippo/YAP signaling pathway, including LATS kinase activity.

Main Results:

• ACADL functions as a tumor suppressor in LUAD, inhibiting cell proliferation and enhancing apoptosis induced by chemotherapeutic drugs.
• ACADL suppresses PD-L1 expression in LUAD, thereby preventing tumor immune evasion.
• ACADL regulates PD-L1 transcription through the Hippo/YAP pathway by increasing LATS kinase activity, which inhibits YAP activation.
• Higher ACADL expression correlates with improved overall survival and progression-free survival in LUAD patients.

Conclusions:

• ACADL acts as a tumor suppressor in LUAD by inhibiting proliferation and immune evasion.
• ACADL's suppression of PD-L1 expression, mediated by the Hippo/YAP pathway, is a key mechanism for preventing immune evasion in LUAD.
• ACADL represents a promising therapeutic target for modulating the Hippo/YAP pathway to enhance LUAD treatment outcomes.